CEL-SCI Corporation news

   Watch this stock
Showing stories 11 - 20 of about 88   

Articles published

CVM 1.89 +0.09 (4.70%)
price chart
CEL-SCI Corp (CVM) Responds to FDA for Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE: CVM) today announced that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study with ...
CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial  Seeking Alpha
Vienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial
Cel-Sci, led by CEO Geert Kersten, has said it spent more than a decade and $80 million in developing and validating the manufacturing process for Multikine.
CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical ...
On October 3, 2017, Lake Whillans Litigation Funding and CEL-SCI agreed to give an incentive to the law firm, Wilk Auslander, which is handling the case for CEL-SCI against the former CRO. Pursuant to this new arrangement, Lake Whillans has agreed to ...
CEL-SCI Corp (CVM) Says FDA Removes Clinical Hold on Phase 3 Head & Neck ...
CEL-SCI Corporation (NYSE: CVM) today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company's Phase 3 cancer study with Multikine* (Leukocyte Interleukin ...
CEL-SCI Corporation (CVM) Stock: Gaining Big On FDA News  CNA Finance (press release)
FDA lifts hold on Cel-Sci's clinical trial for head and neck cancer drug  Washington Business Journal
CEL-SCI Corporation (NYSEMKT:CVM): What Is Price Telling Us?
CEL-SCI Corporation (NYSEMKT:CVM) has had a noteworthy run year to date. The company started out 2017 at around $0.07 a share, and has since gained to trade above $0.11 - a 60% gain across the period.
The Saga Of CEL-SCI Corporation (NYSEMKT:CVM)'S Bleak Clinical Trials  Journal Transcript
CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases ...
Risks And Rewards For Cel-Sci: Phase III And Phase I Progress, And Arbitration
Cel-Sci Corporation (NYSEMKT:CVM), is a clinical stage bio-pharma company with a lead drug candidate (Multikine´┐Ż) currently in the process of a long and slowly populated Phase III study for its effectiveness as a supplemental treatment for Head and ...
CEL-SCI Announces Resignation of its Founder for Health Reasons
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that its founder, President and Chairman of the Board, Maximilian de Clara has resigned for personal health reasons, effective immediately.
CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which ...
The Fundamental Case for and Against CEL-SCI Corporation (CVM)  StockNewsGazette
Analyst Research Roundup: Sucampo Pharmaceuticals, Inc. (SCMP), CEL-SCI ...
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) tinted gains of +2.56% (+0.4 points) to US$16. The volume of 3.43 Million shares climbed down over an trading activity of 896.09 Million shares.